Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(10):779-780; doi:10.1093/jnci/dji136
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bojesen, S. E.
Right arrow Articles by Nordestgaard, B. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bojesen, S. E.
Right arrow Articles by Nordestgaard, B. G.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer

Stig Egil Bojesen, Anne Tybjærg-Hansen, Børge Grønne Nordestgaard

Affiliations of authors: Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark (SEB, BGN); The Copenhagen City Heart Study, Bispebjerg University Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark (AT-H, BGN); Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark (AT-H)

Correspondence to: Børge G. Nordestgaard, Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark (e-mail: brno@herlevhosp.kbhamt.dk).

The first 10% of the full text of this article appears below.

We thank Wang-Gohrke and Chang-Claude for their interesting comments to our article on integrin {beta}3 Leu33Pro homozygosity and increased risk for all cancer (1). In an exploratory posthoc analysis of 27 specific cancer types, we observed that women who carry the polymorphism (homozygotes) had a higher risk for ovarian cancer than noncarriers (hazard ratio [HR] = 4.7, 95% confidence interval [CI] = 1.6 to 14); however, this estimate was based on . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer
Qianren Jin, Kari Hemminki, Ewa Grzybowska, Rüdiger Klaes, Magnus Söderberg, and Asta Försti
J Natl Cancer Inst 2004 96: 234-235. [Extract] [Full Text] [PDF]

Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer
Shan Wang-Gohrke and Jenny Chang-Claude
J Natl Cancer Inst 2005 97: 778-779. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
S E Bojesen, S K Kjaer, E V S Hogdall, B L Thomsen, C K Hogdall, J Blaakaer, A Tybjaerg-Hansen, and B G Nordestgaard
Increased risk of ovarian cancer in integrin {beta}3 Leu33Pro homozygotes
Endocr. Relat. Cancer, December 1, 2005; 12(4): 945 - 952.
[Abstract] [Full Text] [PDF]